International AIDS Vaccine Initiative

Recent papers from International AIDS Vaccine Initiative

1. Sequential vaccination matures VRC01-class HIV-1 neutralizing antibodies in humans2026
2. Translating Innovation to Clinic: End‐to‐End Bioprocess Development and cGMP Manufacturing of N332‐GT5 HIV Vaccine Candidate for First‐In‐Human Trials (HVTN144)Biotechnology and Bioengineering · 2026
3. Safety and Immunogenicity of an rVSV Lassa Fever Vaccine CandidateNew England Journal of Medicine · 2025
4. Long-term malaria exposure in pathogen-endemic environments is associated with distinct immune statesCommunications Biology · 2026
5. Scalable Production of a De Novo SARS-CoV-2 Antiviral Miniprotein in Escherichia coliPharmaceutics · 2026
6. Multifunctional antibody responses from a primate Shigella outbreak inform vaccine designScience Translational Medicine · 2026
7. Automation and autonomy in the IVF laboratory: concepts and implications for embryologistsReproductive BioMedicine Online · 2026
8. Antigen avidity potentiates the durability of the vaccine immune responseScience Translational Medicine · 2026
9. Immunization with mosaic nanoparticles reveals that antigen avidity shapes the clonal hierarchy of the B cell responseScience Translational Medicine · 2026
10. Directed evolution of a stem-helix–targeting antibody enables MERS-CoV cross-neutralization through enhanced binding affinityPLoS Pathogens · 2026
11. Protective pan-betacoronavirus neutralizing antibodies by vaccination2026
12. Structural basis of membrane engagement and polyreactivity control in HIV-1 MPER broadly neutralizing antibodiesProceedings of the National Academy of Sciences · 2026
13. Development and Qualification of a VSV-N IgG ELISA to Assess Vector-Directed Humoral Immunity in VSV-Vectored Vaccine StudiesVaccines · 2026
14. Vaccination elicits HIV broadly neutralizing antibodies in primatesNature · 2026
15. Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN1442026
16. Larger Acute Phase Reactions Are Associated with Immunogenicity of an Adjuvanted Recombinant Receptor Binding Domain Protein Vaccine Against SARS-CoV-2 in Rhesus MonkeysVaccines · 2026
17. Atomic layer deposition for core-shell microparticle vaccines enabling programmable antigen delivery to lymph nodes enhance humoral immune responses2026
18. Heterologous betacoronavirus spike immunization in non-human primates elicits antibodies that neutralize both sarbeco- and merbecovirusesCell Reports · 2026
19. Sudan virus disease in humansThe Lancet Global Health · 2026
20. Searching for immune correlates in Lassa vaccine development – workshop reportnpj Vaccines · 2026